#1 Clinical Trials Search in Europe

Bendamustine Hydrochloride

Bendamustine Hydrochloride is an anticancer drug being studied in clinical trials for treating various types of cancer, including lymphomas, leukemias, and ovarian cancer. This article summarizes key information from several clinical trials investigating the efficacy and safety of Bendamustine Hydrochloride in different patient populations and cancer types.

Table of Contents

What is Bendamustine Hydrochloride?

Bendamustine Hydrochloride is a medication used in the treatment of various types of cancer, particularly blood cancers. It is known by several brand names, including Treanda, Bendeka, and Belrapzo[1]. This drug is classified as a bifunctional alkylating agent, which means it works in multiple ways to combat cancer cells[2].

How Does Bendamustine Work?

Bendamustine works by damaging the DNA of cancer cells. It does this in several ways:

  • It cross-links (connects) DNA strands, both single and double strands, through a process called alkylation.
  • This damage disrupts the function and synthesis of DNA in cancer cells.
  • It also causes DNA to bind with proteins and proteins to bind with other proteins, further interfering with cancer cell function.

These actions combined have the potential to destroy various types of tumor cells[2]. In simpler terms, bendamustine acts like a wrench in the machinery of cancer cells, preventing them from growing and dividing properly.

What Conditions Does Bendamustine Treat?

Bendamustine Hydrochloride is used to treat several types of blood cancers and lymphomas. These include:

  • Chronic Lymphocytic Leukemia (CLL): A type of cancer that affects white blood cells called lymphocytes[3].
  • Non-Hodgkin’s Lymphoma (NHL): A group of blood cancers that develop in the lymphatic system. Bendamustine is particularly used for indolent (slow-growing) forms of NHL[1].
  • Diffuse Large B-Cell Lymphoma (DLBCL): An aggressive type of NHL[4].
  • Multiple Myeloma: A cancer of plasma cells, which are a type of white blood cell[5].
  • Hodgkin’s Lymphoma: A cancer of the lymphatic system[6].

It’s also being studied for use in other conditions, such as ovarian cancer[7].

How is Bendamustine Administered?

Bendamustine Hydrochloride is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The specific dosage and schedule can vary depending on the condition being treated and individual patient factors. However, a common regimen might look like this:

  • The drug is usually given on days 1 and 2 of a 21-day or 28-day cycle.
  • Each infusion typically lasts about 30-60 minutes.
  • The dose is often between 90-120 mg per square meter of body surface area.
  • Treatment may continue for 6-8 cycles, but this can be adjusted based on how well the patient responds and tolerates the treatment[2][4].

Efficacy of Bendamustine

Clinical trials have shown promising results for bendamustine in treating various blood cancers. For example:

  • In patients with chronic lymphocytic leukemia, bendamustine has shown high overall response rates[3].
  • For non-Hodgkin’s lymphoma patients who didn’t respond well to other treatments, bendamustine has demonstrated effectiveness[1].
  • In older patients with diffuse large B-cell lymphoma, bendamustine combined with another drug called rituximab has shown promising results[4].

It’s important to note that the effectiveness can vary depending on the specific type of cancer, its stage, and individual patient factors.

Potential Side Effects

Like all medications, bendamustine can cause side effects. Some of the more common ones include:

  • Hematological toxicities: This means it can affect your blood cells, potentially leading to anemia (low red blood cells), increased risk of infections (due to low white blood cells), or bleeding problems (due to low platelets).
  • Fatigue: Feeling very tired is a common side effect.
  • Nausea and vomiting
  • Loss of appetite
  • Fever

Your healthcare team will monitor you closely for these and other potential side effects[8].

Ongoing Research and Clinical Trials

Researchers continue to study bendamustine to understand its full potential. Some areas of ongoing research include:

  • Combining bendamustine with other drugs to potentially enhance its effectiveness. For example, studies are looking at combining it with drugs like ofatumumab for chronic lymphocytic leukemia[9].
  • Using bendamustine in different types of cancers, such as ovarian cancer[7].
  • Studying its effectiveness in specific patient populations, like older patients with lymphoma[4].
  • Investigating its use in patients whose cancer has returned after or didn’t respond to other treatments[1].

These ongoing studies help doctors and researchers understand more about how to use bendamustine most effectively and safely.

Aspect Details
Cancer Types Studied Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ovarian Cancer
Administration Method Intravenous infusion, typically over 30-60 minutes
Common Dosage 90-120 mg/m² on days 1 and 2 of each treatment cycle
Treatment Cycle Length 21-28 days, depending on the specific trial
Primary Outcomes Measured Overall Response Rate, Progression-Free Survival, Overall Survival
Common Side Effects Low blood cell counts, fatigue, nausea, vomiting
Combination Therapies Studied with rituximab, everolimus, and other anticancer drugs
Patient Populations Often focuses on relapsed or refractory cancers, or patients ineligible for standard treatments

FAQ

  • What types of cancer is Bendamustine Hydrochloride being studied for? Bendamustine Hydrochloride is being studied for various types of cancer, including non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, and ovarian cancer.
  • How is Bendamustine Hydrochloride administered in clinical trials? In most trials, Bendamustine Hydrochloride is administered intravenously (through a vein) over 30-60 minutes. The dosage and frequency vary depending on the specific trial and cancer type, but it is often given on days 1 and 2 of each treatment cycle, with cycles repeating every 21 or 28 days.
  • What are some common side effects of Bendamustine Hydrochloride? Common side effects may include low blood cell counts (which can increase the risk of infection, anemia, and bleeding), fatigue, nausea, and vomiting. Some patients may experience more severe side effects, which are closely monitored during clinical trials.
  • How effective is Bendamustine Hydrochloride in treating cancer? The effectiveness of Bendamustine Hydrochloride varies depending on the type of cancer and individual patient factors. Clinical trials are designed to measure outcomes such as overall response rate, progression-free survival, and overall survival. Some trials have shown promising results, particularly in certain types of lymphomas and leukemias.
  • Can Bendamustine Hydrochloride be combined with other cancer treatments? Yes, some clinical trials are investigating the use of Bendamustine Hydrochloride in combination with other cancer treatments, such as rituximab for lymphomas or everolimus for hematologic cancers. These combination therapies aim to improve treatment efficacy and outcomes for patients.

Ongoing Clinical Trials on Bendamustine Hydrochloride

  • Study Comparing Axicabtagene Ciloleucel with Standard Treatment for Patients with Relapsed or Refractory Follicular Lymphoma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study Comparing Venetoclax and Obinutuzumab with Drug Combination for Fit Patients with Untreated Chronic Lymphocytic Leukemia Without Specific Genetic Mutations

    Not recruiting

    3 1 1 1
    Investigated drugs:
    France Italy Spain

  • Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Austria France Germany Italy Spain

  • Study on Loncastuximab Tesirine for Patients with Relapsed or Refractory Mantle Cell Lymphoma After Immunochemotherapy with Rituximab, Bendamustine, and Cytarabine

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Rituximab, Bendamustine, Cytarabine, and Venetoclax for High-Risk Elderly Patients with Mantle Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study Comparing Rituximab with Ibrutinib to Rituximab with Chemotherapy for Older Patients with Untreated Mantle Cell Lymphoma

    Not recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Finland Norway Sweden

  • Study on the Effectiveness and Safety of Golcadomide and Rituximab for Patients with Newly Diagnosed Advanced Follicular Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Denmark Finland France Germany +7

  • Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia Denmark France +11

  • Study of Tisagenlecleucel for Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Italy The Netherlands Norway +1

Glossary

  • Bendamustine Hydrochloride: An anticancer drug that belongs to the class of alkylating agents. It works by damaging the DNA of cancer cells, which can lead to cell death and slow or stop tumor growth.
  • Clinical Trial: A research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis, or treatment of a disease.
  • Non-Hodgkin's Lymphoma (NHL): A type of cancer that starts in white blood cells called lymphocytes, which are part of the body's immune system.
  • Chronic Lymphocytic Leukemia (CLL): A type of cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell.
  • Multiple Myeloma: A cancer that forms in a type of white blood cell called a plasma cell. These cancerous plasma cells accumulate in the bone marrow.
  • Acute Lymphoblastic Leukemia (ALL): A type of cancer of the blood and bone marrow that affects white blood cells. It progresses rapidly and requires immediate treatment.
  • Ovarian Cancer: A type of cancer that begins in the ovaries, which are part of the female reproductive system.
  • Intravenous (IV): A method of administering medications or fluids directly into a vein.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or level of treatment.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects.
  • Refractory Cancer: Cancer that does not respond to treatment. The cancer may be resistant at the beginning of treatment or it may become resistant during treatment.
  • Relapsed Cancer: Cancer that returns after a period of improvement.

References

  1. https://clinicaltrials.gov/study/NCT00139841
  2. https://clinicaltrials.gov/study/NCT04569838
  3. https://clinicaltrials.gov/study/NCT01131247
  4. https://clinicaltrials.gov/study/NCT01234467
  5. https://clinicaltrials.gov/study/NCT02240719
  6. https://clinicaltrials.gov/study/NCT00705250
  7. https://clinicaltrials.gov/study/NCT00867503
  8. https://clinicaltrials.gov/study/NCT01596621
  9. https://clinicaltrials.gov/study/NCT01125787